Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.
Prekovic S, Chalkiadakis T, Roest M, Roden D, Lutz C, Schuurman K, Opdam M, Hoekman L, Abbott N, Tesselaar T, Wajahat M, Dwyer AR, Mayayo-Peralta I, Gomez G, Altelaar M, Beijersbergen R, Győrffy B, Young L, Linn S, Jonkers J, Tilley W, Hickey T, Vareslija D, Swarbrick A, Zwart W.
Prekovic S, et al.
EMBO Mol Med. 2023 Dec 7;15(12):e17737. doi: 10.15252/emmm.202317737. Epub 2023 Oct 30.
EMBO Mol Med. 2023.
PMID: 37902007
Free PMC article.
Notably, GR activation leads to upregulation of the ZBTB16 gene, encoding for a transcriptional repressor, which controls growth in ER-positive breast cancer and associates with prognosis in luminal A patients. In relation to ZBTB16's repressive nature, GR activation leads …
Notably, GR activation leads to upregulation of the ZBTB16 gene, encoding for a transcriptional repressor, which controls growth in ER-posit …